Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128878 | 0.90 | CYP2C9 (0.54) | CYP2C9MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL9399116 | 0.82 | CYP2C9 (0.54) | CYP2C9MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10579686 | 0.82 | CYP2C9 (0.54) | CYP2C9MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10618609 | 0.82 | CYP2C9 (0.50) | CYP2C9MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11199910 | 0.81 | SPHK1 (0.54) | CYP2C9MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11192887 | 0.81 | CYP2C9 (0.53) | CYP2C9MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11193199 | 0.81 | SPHK1 (0.54) | CYP2C9MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11199904 | 0.81 | SPHK1 (0.54) | CYP2C9MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11196171 | 0.81 | SPHK1 (0.54) | CYP2C9MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11193637 | 0.81 | SPHK1 (0.54) | CYP2C9MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | CYP2C9 348/4885MEN1 4808/4885KMT2A 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.